206 related articles for article (PubMed ID: 32769760)
1. The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection.
Manolis AS; Manolis TA; Manolis AA; Melita H
J Cardiovasc Pharmacol; 2020 Oct; 76(4):397-406. PubMed ID: 32769760
[TBL] [Abstract][Full Text] [Related]
2. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
3. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
4. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
Hooper NM; Lambert DW; Turner AJ
Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
[TBL] [Abstract][Full Text] [Related]
6. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
7. Potential influence of COVID-19/ACE2 on the female reproductive system.
Jing Y; Run-Qian L; Hao-Ran W; Hao-Ran C; Ya-Bin L; Yang G; Fei C
Mol Hum Reprod; 2020 Jun; 26(6):367-373. PubMed ID: 32365180
[TBL] [Abstract][Full Text] [Related]
8. Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.
Barillà F; Bassareo PP; Calcaterra G; Romeo F; Mehta JL
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):630-633. PubMed ID: 32740495
[TBL] [Abstract][Full Text] [Related]
9. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?
Kutti Sridharan G; Kotagiri R; Chandiramani VH; Mohan BP; Vegunta R; Vegunta R; Rokkam VRP
Am J Ther; 2020; 27(4):e400-e402. PubMed ID: 32366740
[TBL] [Abstract][Full Text] [Related]
11. Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.
Hrenak J; Simko F
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126657
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
13. Sex-Specific Modulation of Blood Pressure and the Renin-Angiotensin System by ACE (Angiotensin-Converting Enzyme) 2.
Ji H; de Souza AMA; Bajaj B; Zheng W; Wu X; Speth RC; Sandberg K
Hypertension; 2020 Aug; 76(2):478-487. PubMed ID: 32564694
[TBL] [Abstract][Full Text] [Related]
14. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
Steckelings UM; Sumners C
Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709
[TBL] [Abstract][Full Text] [Related]
15. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
16. ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.
Snyder EM; Johnson BD
Pharmacogenomics; 2020 Jul; 21(10):695-703. PubMed ID: 32501190
[TBL] [Abstract][Full Text] [Related]
17. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
Soto M; diZerega G; Rodgers KE
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972018. PubMed ID: 33169644
[TBL] [Abstract][Full Text] [Related]
18. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
19. Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.
Sparks MA; South AM; Badley AD; Baker-Smith CM; Batlle D; Bozkurt B; Cattaneo R; Crowley SD; Dell'Italia LJ; Ford AL; Griendling K; Gurley SB; Kasner SE; Murray JA; Nath KA; Pfeffer MA; Rangaswami J; Taylor WR; Garovic VD
Hypertension; 2020 Nov; 76(5):1350-1367. PubMed ID: 32981369
[TBL] [Abstract][Full Text] [Related]
20. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients.
Zamai L
Cells; 2020 Jul; 9(7):. PubMed ID: 32708755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
